Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2000 September;42(3) > Panminerva Medica 2000 September;42(3):193-5

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

PANMINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

ORIGINAL ARTICLES  


Panminerva Medica 2000 September;42(3):193-5

lingua: Inglese

The use of intravenous immunoglobulin in sine causa or alloimmune recurrent spontaneous abortion (RSA)

Patriarca A., Piccioni V., Gigante V., Benedetto C.

From the Department of Obstetrics and Gynecology, Chair C University of Turin, Italy


PDF  


Background. Recurrent spon­ta­neous abor­tion (RSA) has an inci­dence of 0.5%-1%. It is th­ought ­that ­immune reac­tion dis­or­ders in the ­mother may ­evolve in unex­plained RSA, ­which has a ­higher inci­dence in ­women ­over 40 ­years old.
Methods. Twenty-­three ­patients ­with recur­rent spon­ta­neous abor­tion of ­unknown ­origin and two auto­im­mune ­cases ­were ­treated ­with intra­ve­nous spe­cific immu­no­glob­u­lins at the 5th-6th ­week of preg­nancy and fif­teen ­days ­later.
Results. After treat­ment, nine­teen ­patients ­brought ­their preg­nancy to ­term, ­five ­aborted, one is preg­nant at ­present.
Conclusions. The use of immu­no­glob­u­lins ­seems to be effi­ca­cious in recur­rent spon­ta­neous abor­tion of ­unknown ­origin. Our ­results sup­port the ­theory ­that ­this treat­ment is ­able to pas­sively ­transfer the ­sparking off ­factor ­that ­allows the preg­nancy to ­evolve.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail